IRAG1-AS1
MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) can affect nasopharyngeal cancer (NPC) paclitaxel chemosensitivity [1]
Contents
Annotated Information
Name
Approved symbol：IRAG1-AS1
Approved name：IRAG1 antisense RNA 1
HGNC ID：HGNC:43434
Previous name：MRVI1 antisense RNA 1 (non-protein coding)|MRVI1 antisense RNA 1
RefSeq ID：NR_034093
prev_symbol：MRVI1-AS1
Characteristics
Please input information here.
Function
The2 MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway.[1].
Regulation
MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity.[1]
MRVI1-AS1 and ATF3 could form a positive feedback loop, which promoted the expression of RASSF1 (Ras association domain family member 1), a Hippo-TAZ (tafazzin) signaling pathway regulatory factor, thereby inhibiting TAZ expression.[1]
Expression
MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity. [1].
Diseases
- nasopharyngeal cancer (NPC) .[1]
Labs working on this lncRNA
- Department of Oncology, Third Xiangya Hospital of Central South University, 410013, Changsha, People's Republic of China.[1]
- Department of Respiration, The Second People's Hospital of Hunan Province of Hunan University of Chinese Medicine, Changsha, 410000, People's Republic of China.[1]
- Institute of Reproductive and Stem Cell Engineering, Central South University, 410083, Changsha, Hunan, People's Republic of China.[1]
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 510060, Guangzhou, People's Republic of China.[1]
- Department of Plastic Surgery, Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, People's Republic of China.[1]
- Department of Gastroenterology, Third Xiangya Hospital of Central South University, 410013, Changsha, People's Republic of China.[1]
- Cancer Research Institute and Key Laboratory of Carcinogenesis of Ministry of Health, Central South University, 410078, Changsha, People's Republic of China.[1]
- School of Public Health, Central South University, 410078, Changsha, Hunan, People's Republic of China.[1]
- Center for Medical Experiments, Third Xiangya Hospital, Central South University, 410013, Changsha, People's Republic of China.[1]
- Yan'an Affiliated Hospital of Kunming Medical University, 650051, Kunming, People's Republic of China.[1]
- Department of Otolaryngology-Head Neck Surgery, Third Xiangya Hospital, Central South University, 410013, Changsha, Hunan, People's Republic of China.[1]
- Department of Oncology, Third Xiangya Hospital of Central South University, 410013, Changsha, People's Republic of China. csucaoke@163.com.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 Zhu Y, He D, Bo H, Liu Z, Xiao M, Xiang L, Zhou J, Liu Y, Liu X, Gong L, Ma Y, Zhou Y, Zhou M, Xiong W, Yang F, Xing X, Li R, Li W, Cao K. The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway. Oncogene. 2019 Aug;38(32):6065-6081. doi: 10.1038/s41388-019-0858-7. Epub 2019 Jul 4. PMID: 31273338.
